Financial Performance - Total revenue for Q2 2024 was $486.3 million, a 40% increase from $348.2 million in Q2 2023[3] - Care Partners revenue reached $463.3 million, up 44% from $321.8 million year-over-year[3] - Net income attributable to Astrana was $19.2 million, reflecting a 46% increase from $13.2 million in the same quarter last year[3] - Adjusted EBITDA for Q2 2024 was $47.9 million, a 34% increase from $35.8 million in Q2 2023[3] - Total revenue for the three months ended June 30, 2024, was $486,265, an increase of 39.7% compared to $348,209 for the same period in 2023[26] - Net income for the three months ended June 30, 2024, was $21,866, representing a 25.7% increase from $17,482 in the same period of 2023[26] - Adjusted EBITDA for the six months ended June 30, 2024, was $90,162,000, a significant increase from $65,599,000 in 2023, reflecting a growth of 37.5%[28] - The company provided guidance for 2024 with a net income range of $62,500,000 to $75,500,000, and an EBITDA range of $137,000,000 to $157,000,000[30] Guidance and Projections - For 2024, the company updated its revenue guidance to a range of $1.75 billion to $1.85 billion[10] - Net income guidance for 2024 is set between $54 million and $66 million, with diluted EPS guidance of $1.12 to $1.36[10] - Adjusted EBITDA guidance for 2024 is projected between $165 million and $185 million[10] Assets and Liabilities - Total current assets increased to $570,349 as of June 30, 2024, up from $461,507 as of December 31, 2023, reflecting a growth of 23.6%[21] - Total assets reached $1,252,471 as of June 30, 2024, compared to $933,361 as of December 31, 2023, marking a significant increase of 34.2%[24] - Total liabilities increased to $773,775 as of June 30, 2024, from $522,593 as of December 31, 2023, indicating a rise of 47.9%[24] - Cash and cash equivalents rose to $325,310 as of June 30, 2024, compared to $293,807 as of December 31, 2023, an increase of 10.7%[21] - Total non-current assets increased to $682,122 as of June 30, 2024, from $471,854 as of December 31, 2023, a growth of 44.5%[21] - The company’s total stockholders' equity increased to $683,008 as of June 30, 2024, from $616,651 as of December 31, 2023, reflecting an increase of 10.7%[24] Operational Developments - The company entered Arizona, partnering with a primary care group serving approximately 50,000 patients, expected to onboard by the end of 2024[4] - Astrana announced a partnership with Anthem Blue Cross to improve access to healthcare through new primary care clinics[5] - The acquisition of Collaborative Health Systems is anticipated to close in Q4 2024, expanding care delivery capabilities for over 100,000 beneficiaries[6] Other Financial Metrics - Earnings per share (diluted) for the three months ended June 30, 2024, was $0.40, compared to $0.28 for the same period in 2023, representing a growth of 42.9%[26] - The company reported a capitation revenue of $442,574 for the three months ended June 30, 2024, up from $300,549 in the same period of 2023, reflecting a growth of 47.1%[26] - Interest expense increased to $8,587,000 for the three months ended June 30, 2024, compared to $3,632,000 in the same period last year, marking a rise of 136.5%[28] - Provision for income taxes decreased to $10,031,000 for the three months ended June 30, 2024, down from $14,009,000 in 2023, a decline of 28.4%[28] - Stock-based compensation for the three months ended June 30, 2024, was $7,390,000, an increase of 75.1% from $4,213,000 in the prior year[28] - Other net for the three months ended June 30, 2024, was $(2,983,000), compared to $(1,618,000) in the same period of 2023, indicating increased non-cash changes[28] - The company emphasizes the use of non-GAAP financial measures like Adjusted EBITDA to provide a clearer picture of operational performance[31]

Financial Performance - Total revenue for Q1 2024 was $404.4 million, an increase of $67.1 million or 20% compared to $337.2 million in Q1 2023[198] - Capitation revenue increased by $65.7 million to $365.9 million, primarily due to recent acquisitions[194] - Operating expenses totaled $374.2 million, up $59.3 million or 19% from $314.9 million in Q1 2023[195] - Net income attributable to Astrana Health, Inc. was $14.8 million, a 13% increase from $13.1 million in Q1 2023[210] - Care Partners segment revenue grew by 26% to $397.1 million, reflecting strong performance in the company's core operations[212] - Care Partners segment revenue increased to $397.1 million for Q1 2024, up 26% from $314.7 million in Q1 2023, with operating income rising 94% to $43.2 million[214] - Care Delivery segment revenue grew to $30.7 million in Q1 2024, a 21% increase from $25.4 million in Q1 2023, with operating loss reduced by 75% to $0.2 million[215] - Care Enablement segment revenue reached $33.3 million in Q1 2024, up from $30.6 million in Q1 2023, but operating income decreased by 39% to $3.5 million[216] Expenses and Income - General and administrative expenses rose by $17.5 million or 83% to $38.7 million, driven by operational growth[200] - Interest expense increased to $7.6 million, up 132% from $3.3 million in Q1 2023, due to higher borrowings[203] Cash Flow and Investments - Cash, cash equivalents, and marketable securities totaled $337.3 million as of March 31, 2024, an increase from $296.3 million at the end of 2023[224] - Net cash provided by operating activities was $5.977 million in Q1 2024, down 23% from $7.720 million in Q1 2023[228] - Cash used in investing activities surged to $71.039 million in Q1 2024, compared to $14.035 million in Q1 2023, primarily due to business acquisitions[230] - Cash provided by financing activities was $106.351 million in Q1 2024, a significant increase from a cash outflow of $7.099 million in Q1 2023[231] Debt and Financing - Total debt as of March 31, 2024, was $393.259 million, with long-term debt amounting to $368.448 million after accounting for current portions and unamortized financing costs[234] - The Amended Credit Agreement provides a five-year revolving credit facility of $400 million, increasing the total facility to $700 million after a new term loan of up to $300 million was added[236] - As of March 31, 2024, borrowings under the Term Loan were $296.5 million, with an interest rate ranging from 1.50% to 2.75% based on the Company's Consolidated Total Net Leverage Ratio[242] - The Company borrowed $94.8 million under the Revolver Loan, with interest rates ranging from 1.25% to 2.50% based on the same leverage ratio[242] - A hypothetical 1% change in interest rates would have impacted the Company's interest expense by $3.9 million for the three months ended March 31, 2024[242] - The Company has a promissory note payable of $2 million, maturing on May 9, 2024[237] Projections and Guidance - The company projects total revenue for 2024 to be between $1.65 billion and $1.85 billion, with net income expected between $61 million and $73 million[218] - Adjusted EBITDA for 2024 is guided to be between $165 million and $185 million, with diluted EPS projected between $1.28 and $1.52[218] Acquisitions - The acquisition of Community Family Care (CFC) was completed on March 31, 2024, marking the largest acquisition in the company's history[187] Patient Management - The company managed approximately 1.0 million patients as of March 31, 2024, down from 1.3 million in the same period last year[197] Accounting Policies - Critical accounting policies and estimates are integral to understanding the financial statements, reflecting significant judgments and uncertainties[239] - The Company’s management is required to make judgments and estimates that could lead to materially different results under varying assumptions[239] Off-Balance Sheet Arrangements - As of March 31, 2024, there were no off-balance sheet arrangements that could materially affect the Company's financial condition[240] Risk Management - The Company has entered into a collar agreement for its Revolver Loan to convert floating-rate debt to a fixed-rate basis, aiming to reduce variability in cash flows[242]

Exhibit 99.1 Astrana Health, Inc. Reports First Quarter 2024 Results Company to Host Conference Call on Tuesday, May 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., May 7, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated fina ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|--------------------------------------| | | | | for the tra ...

Sometimes, the best trading advice can come from a list of stocks owned by Congress. If they are buying, you may want to look into it. Politicians seem to have an uncanny, remarkable track record of success.For example, on Nov. 22, Rep. Nancy Pelosi bought 50 Nvidia (NASDAQ:NVDA) 20 Dec 2024 $120 call options even as the underlying stock traded at a high of $503.31. Today, NVDA stock trades around $784. Had you followed her into NVDA, you stood to make a good deal of money. Granted, not all of her trades wo ...

Exhibit 99.1 Astrana Health, Inc. Reports Fourth Quarter and Year-End 2023 Results Company to Host Conference Call on Tuesday, Feb. 27, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., February 27, 2024 /PRNewswire/ -- Astrana Health, Inc. (together with its subsidiaries and affiliated entities, "Astrana") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced its consolidated financi ...

Apollo Medical Holdings, Inc. (AMEH) shares rallied 7.6% in the last trading session to close at $41.70. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.6% gain over the past four weeks.Apollo Medical Holdings, Inc. scored a strong price increase, on investors’ optimism driven by the company’s announcement of officially changing its name to Astrana Health, Inc. The unifying brand reflects the company’s grow ...

Core Insights - Elevance Health (ELV) is currently rated as a better investment option compared to Apollo Medical Holdings, Inc. (AMEH) based on Zacks Rank and valuation metrics [1][3] Valuation Metrics - ELV has a forward P/E ratio of 13.83, significantly lower than AMEH's forward P/E of 27.31, indicating that ELV may be undervalued [2] - The PEG ratio for ELV is 1.15, while AMEH's PEG ratio is 2.38, suggesting that ELV has a more favorable earnings growth outlook relative to its price [2] - ELV's P/B ratio stands at 3.06, compared to AMEH's P/B of 3.71, further supporting the argument that ELV is a more attractive value stock [2] Investment Outlook - ELV is currently experiencing an improving earnings outlook, which enhances its attractiveness as a value investment [3] - The overall Value grade for ELV is A, while AMEH has a Value grade of C, indicating a stronger position for ELV in the value investment category [2][3]

Leadership Transitions - Apollo Medical Holdings, Inc. announced leadership changes, with Brandon Sim becoming President and CEO, effective January 19, 2024 [1][2] - Dr. Thomas Lam, co-founder and former President and Co-CEO, will retire and serve as Vice Chairman of the Board [1][2] - Chan Basho remains CFO and is now also the Chief Operating Officer [1] - Dr. Dinesh Kumar has been appointed as Chief Medical Officer, effective January 23, 2024 [1][4] Company Growth and Vision - Dr. Lam played a crucial role in ApolloMed's transformation from a regional organization to a national integrated healthcare platform serving over 10,000 providers [2] - Brandon Sim is expected to lead the company into its next growth phase, supported by Chan Basho and Dr. Dinesh Kumar [2][3] - The leadership transition is part of a planned process aimed at enhancing ApolloMed's value-based healthcare model [2][3] Executive Insights - Dr. Lam expressed pride in the high-quality healthcare provided by ApolloMed and confidence in Sim's leadership capabilities [3] - Sim acknowledged Dr. Lam's contributions to the healthcare industry and emphasized the importance of continuing to deliver exceptional care [3] - Sim highlighted the significance of Chan Basho's role in scaling the company and expressed excitement about working with Dr. Kumar [3][4] Dr. Dinesh Kumar's Background - Dr. Kumar brings over 25 years of healthcare experience, having previously served in leadership roles at Alignment Healthcare and DaVita [5] - His expertise includes value-based care and population health, which will support ApolloMed's mission to enhance care delivery [5][6] Company Overview - ApolloMed is a technology-powered healthcare company focused on providing accessible, high-quality, and high-value care [7] - The company operates an integrated healthcare delivery platform that enables providers to participate in value-based care arrangements [7]

Core Points - Apollo Medical Holdings, Inc. plans to change its name to Astrana Health effective February 26, 2024, with its common stock to trade under the new symbol "ASTH" on NASDAQ [1] - Astrana Health serves approximately 900,000 members in value-based care arrangements and partners with over 10,000 affiliated providers, operating 61 outpatient locations nationwide [2] - The new brand, Astrana Health, symbolizes a unifying identity reflecting the company's commitment to high-quality care and its expanding national presence [3] Company Overview - Apollo Medical Holdings, Inc. is a technology-powered healthcare company that enables providers to deliver accessible, high-quality, and high-value care [5] - The company operates an integrated healthcare delivery platform that supports providers in participating in value-based care arrangements [5] - ApolloMed's subsidiaries include management services organizations (MSOs) and independent practice associations (IPAs) [5]